Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John H L Matthews

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The New Zealand Medical Journal|November 5, 2013
Barrie David EvansJohn H L Matthews
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 3, 2006
Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology GroupNirdosh Kumar Gogna, John H L Matthews, Sandra L Turner, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 27, 2010
T1-2 anal carcinoma requires elective inguinal radiation treatment--the results of Trans Tasman Radiation Oncology Group study TROG 99.02John H L Matthews, Bryan H Burmeister, Martin Borg, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 30, 2007
The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397)David P Dearnaley, Matthew R Sydes, Ruth E Langley, et al.
Oncology Research|June 23, 2004
Estimation of radiation-induced interphase cell death in cultures of human tumor material and in cell linesElaine S Marshall, Bruce C Baguley, John H L Matthews, et al.
The Lancet. Oncology|March 4, 2014
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trialDavid P Dearnaley, Gordana Jovic, Isabel Syndikus, et al.
International Journal of Radiation Oncology, Biology, Physics|February 25, 2020
Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR TrialDavid Joseph, James W Denham, Allison Steigler, et al.
The Lancet. Oncology|October 1, 2020
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trialAndrew Kneebone, Carol Fraser-Browne, Gillian M Duchesne, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The New Zealand Medical Journal|November 5, 2013
Barrie David EvansJohn H L Matthews
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 3, 2006
Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology GroupNirdosh Kumar Gogna, John H L Matthews, Sandra L Turner, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 27, 2010
T1-2 anal carcinoma requires elective inguinal radiation treatment--the results of Trans Tasman Radiation Oncology Group study TROG 99.02John H L Matthews, Bryan H Burmeister, Martin Borg, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 30, 2007
The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397)David P Dearnaley, Matthew R Sydes, Ruth E Langley, et al.
Oncology Research|June 23, 2004
Estimation of radiation-induced interphase cell death in cultures of human tumor material and in cell linesElaine S Marshall, Bruce C Baguley, John H L Matthews, et al.
The Lancet. Oncology|March 4, 2014
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trialDavid P Dearnaley, Gordana Jovic, Isabel Syndikus, et al.
International Journal of Radiation Oncology, Biology, Physics|February 25, 2020
Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR TrialDavid Joseph, James W Denham, Allison Steigler, et al.
The Lancet. Oncology|October 1, 2020
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trialAndrew Kneebone, Carol Fraser-Browne, Gillian M Duchesne, et al.
Pageof 1